just my thought,
there would not be a takeover offer - should be partnering deals - unless (i) NEU split the second drug to a new subsidiary or new entity (yet to finalise and more powerful then the existing one). (ii) the offer takes into consideration drugs in pipeline
Release Today Neuren Valuation Estimate Raised, page-46
Add to My Watchlist
What is My Watchlist?
